CAS 73963-72-1

Cilostazol

Description:

Cilostazol is a phosphodiesterase III inhibitor primarily used as a medication to treat intermittent claudication, a condition characterized by pain in the legs due to inadequate blood flow. It works by promoting vasodilation and inhibiting platelet aggregation, thereby improving blood flow and reducing symptoms associated with reduced circulation. Cilostazol is typically administered orally and is known for its relatively short half-life, necessitating multiple doses throughout the day for effective management of symptoms. The chemical structure of cilostazol includes a benzothiazole moiety, contributing to its pharmacological properties. It is generally well-tolerated, although some patients may experience side effects such as headache, diarrhea, or palpitations. Due to its mechanism of action, cilostazol is contraindicated in patients with heart failure and should be used cautiously in those with a history of cardiovascular issues. Overall, cilostazol represents a significant therapeutic option for enhancing mobility and quality of life in individuals suffering from peripheral artery disease.

Formula: C₂₀H₂₇N₅O₂

InChI: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key: InChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N

SMILES: C(CCCOC=1C=C2C(=CC1)NC(=O)CC2)C=3N(N=NN3)C4CCCCC4

Synonyms:

• 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
• 6-[4-(1-Cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
• 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
• 6-[4-(1-Cyclohexyl-5-Tetrazolyl)Butoxy]-1,2,3,4-Tetrahydro-2-Oxoquinolinone
• 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
• Cilostazole
• Opc 13013
• Opc 21
• Pletaal
• Pletal
• Cilostazol

Cilostazol

CAS: 73963-72-1

Formula: C₂₀H₂₇N₅O₂

Purity: >98.0%(HPLC)

Color and Shape: White to Almost white powder to crystal

Molecular weight: 369.47

Ref: 3B-C2587

Cilostazol

CAS: 73963-72-1

Color and Shape: Neat

Ref: 61-FOR0796.00

Cilostazol

CAS: 73963-72-1

Lactams not elsewhere specified or included

Formula: C₂₀H₂₇N₅O₂

Color and Shape: White Off-White Crystalline Powder

Molecular weight: 369.21648

Ref: 45-1134153

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

CAS: 73963-72-1

Formula: C₂₀H₂₇N₅O₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 369.4607

Ref: IN-DA003OWJ

Cilostazol

CAS: 73963-72-1

Cilostazol (OPC 21) is a Phosphodiesterase 3 Inhibitor. The mechanism of action of cilostazol is as a Phosphodiesterase 3 Inhibitor.

Formula: C₂₀H₂₇N₅O₂

Purity: 99.58% - 99.90%

Color and Shape: Off-White Solid

Molecular weight: 369.46

Ref: TM-T0462

Cilostazol

CAS: 73963-72-1

Cilostazol

Purity: ≥98%

Molecular weight: 369.46g/mol

Ref: 54-BUP11876

Cilostazol

CAS: 73963-72-1

Formula: C₂₀H₂₇N₅O₂

Purity: ≥ 98.0%

Color and Shape: White to off-white powder or crystals

Molecular weight: 369.46

Ref: 7W-GP7846

Cilostazol

CAS: 73963-72-1

Cilostazol

Formula: C₂₀H₂₇N₅O₂

Purity: 99% (Typical Value in Batch COA)

Color and Shape: white powder

Molecular weight: 369.46g/mol

Ref: 54-BI7396

Cilostazol

CAS: 73963-72-1

Formula: C₂₀H₂₇N₅O₂

Color and Shape: White To Off-White Solid

Molecular weight: 369.47

Ref: 4Z-C-071

Cilostazol

CAS: 73963-72-1

Formula: C₂₀H₂₇N₅O₂

Color and Shape: Neat

Molecular weight: 369.46

Ref: 86-MM0796.00

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one

CAS: 73963-72-1

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one

Purity: 98%

Color and Shape: Solid

Molecular weight: 369.46g/mol

Ref: 54-OR13681

Cilostazol RS

CAS: 73963-72-1

Color and Shape: White To Pale Yellow-White

Ref: 2K-1071000021

Cilostazol

Controlled Product

CAS: 73963-72-1

Applications A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo. Neuroprotective & Neuroresearch product.
References Suri, A., et al.: J. Clin. Pharmacol., 38, 144 (1998), Park, S.-W., et al.: Am. J. Cardiol., 84, 511 (1999), Tsuchikane, E., et al.: Circulation, 100, 21 (1999),

Formula: C₂₀H₂₇N₅O₂

Color and Shape: Neat

Molecular weight: 369.46

Ref: TR-C441500

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

CAS: 73963-72-1

Cilostazol is a drug that binds to ATP-binding cassette (ABC) transporters, which are proteins that transport molecules across membranes. It decreases the production of cyclic nucleotides and phosphodiesterase, which are important in the regulation of blood vessel tone. Cilostazol has been shown to be effective in treating heart failure and atherosclerosis. Cilostazol also inhibits cyclase activity, an enzyme involved in the synthesis of cyclic nucleotides, which leads to vasodilation by increasing the concentration of cAMP. The drug is available in both immediate-release and controlled-release preparations. Cilostazol can have serious side effects such as congestive heart failure or stroke if it is taken with other drugs that inhibit platelet aggregation such as aspirin or warfarin.

Formula: C₂₀H₂₇N₅O₂

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 369.46 g/mol

Ref: 3D-FC03161

Cilostazol

CAS: 73963-72-1

Purity: 98%

Molecular weight: 369.4689941

Ref: 10-F862750